Cerivastatin-Induced Rhabdomyolysis
The DOI matches its Crossref record.
Abstract
Letters4 April 2000Cerivastatin-Induced RhabdomyolysisMaría L. Rodríguez, MD, Carmen Mora, MD, and Juan F. Navarro, MDMaría L. Rodríguez, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro), Carmen Mora, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro), and Juan F. Navarro, MDHospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-7-200004040-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Cerivastatin is the last generation of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, the drugs of choice for treating hypercholesterolemia. Tolerability in clinical trials did not differ from that of placebo with regard to serum creatine kinase (CK) levels, and drug-induced myopathy was not reported (1-4). We describe a renal transplant recipient who developed rhabdomyolysis after receiving cerivastatin.In October 1996, a 52-year-old woman with renal failure secondary to polycystic kidney disease had renal transplantation. She was admitted to our hospital in May 1999 for asthenia, myalgia, and muscle weakness. From December 1996 to November 1998 she had ...References1. Stein EA. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs. 1998;56 Suppl 1 25-31. CrossrefMedlineGoogle Scholar2. McClellan KJ, Wiseman LR, McTavish D. Cerivastatin. Drugs. 1998;55:415-20. CrossrefMedlineGoogle Scholar3. Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J Cardiol. 1998;82 Suppl 4B 40-6. CrossrefGoogle Scholar4. Bischoll H, Heller A. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol. 1998;82 Suppl 4B 18-25. CrossrefGoogle Scholar5. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, et al . Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther. 1999;65:251-61. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Rodríguez)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Mora)Hospital Nuestra Señora de Candelaria; 38010 Santa Cruz de Tenerife, Spain (Navarro) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDrug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced FatalitiesHMG coenzyme-A reductase inhibitorsCardiovascular DrugsPotential role for statins in sickle cell diseaseIn silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machineIncidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantationLIPID – REGULATING DRUGSSpecial Patient Populations: Transplant RecipientsHMG coenzyme-A reductase inhibitorsPreventing Cardiovascular Outcome in Patients with Renal ImpairmentEffectiveness of Statin-Gemfibrozil Combination Therapy in Patients With Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review From the LiteratureIatrogenic and toxic myopathiesRhabdomyolysis Associated with Cerivastatin: Six Cases within 3 Months at One HospitalSevere Rhabdomyolysis and Cerivastatin—Gemfibrozil Combination TherapyRisperidone and severe cerivastatin-induced rhabdomyolysisRabdomiólisis inducida por la combinación de cerivastatina y ciclosporinaDrugs that affect lipid metabolismCerivastatin: Rhabdomyolysis: case reportRhabdomyolysis and HMG-CoA Reductase InhibitorsCERIVASTATIN-INDUCED RHABDOMYOLYSIS IN A RENAL TRANSPLANT ON CYCLOSPORINShort-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trialRhabdomyolysis due to cerivastatin monotherapyRabdomiólisis asociada al tratamiento combinado con cerivastatina y gemfibroziloDIALYTIC TREATMENT OF RHABDOMYOLYSIS-INDUCED ACUTE RENAL FAILURE: OUR EXPERIENCECerivastatin 4 April 2000Volume 132, Issue 7Page: 598KeywordsCreatine kinaseDrug interactionsDrugsLactate dehydrogenaseMetabolic pathwaysMetabolitesMusclesRenal transplantationResearch laboratoriesRhabdomyolysis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Outcomes in 45 Patients With Statin-Associated Myopathy
Hansen, K. E., Hildebrand, J. P., Ferguson, E. E., & Stein, J. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2671 · Cited by 280
Li, W., Feng, Y., Feng, Z., Wang, L., Whiteway, M., Lu, H., & Jiang, Y. (2024) · Antioxidants · doi:10.3390/antiox13060667 · Cited by 14
Metadata
- Authors
- Rodríguez, M. L., Mora, C., & Navarro, J. F.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2000-04-04
- Volume
- 132
- Issue
- 7
- Pages
- 598
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2020846860
- Cited by
- 39
- References
- 0
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerivastatin-Induced Rhabdomyolysis. https://app.cochat.ai/papers/10.7326/0003-4819-132-7-200004040-00031
- The paper
- Rodríguez, M. L., Mora, C., & Navarro, J. F. (2000). Cerivastatin-Induced Rhabdomyolysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-132-7-200004040-00031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.